16. Patients who are unwilling to quit may respond well to a directive, patient-centered counseling intervention known as: a. The Four D’s. b. Tobacco integration therapy. c. Motivational interviewing. d. The Fagerström Test for Nicotine Dependence. 17. Nicotine replacement therapy is available as a gum, lozenge, patch, inhaler, and: a. Nasal spray. b. Ointment. c. Eye drop. d. Injection. 18. The use of bupropion SR (Zyban) for smoking cessation is contraindicated in patients with: a. A history of seizures. b. Coronary artery disease. c. Active peptic ulcer disease. d. Chronic obstructive pulmonary disease. 19. The major contributors to the carcinogenic activity of smokeless tobacco are the: a. Benzopyrenes. b. Heavy metals. c. Polynuclear aromatic hydrocarbons. d. Tobacco-specific N-nitrosamines (TSNAs). 20. The most common finding associated with smokeless tobacco use is: a. Mucosal hyperplasia. b. Severe attrition.
11. Stimulation of cholinergic neurons promotes the release of what substance in the reward centers of the brain? a. Dopamine. b. Norepinephrine. c. Epinephrine. d. GABA. 12. Mood modulation and appetite suppression associated with nicotine are due to the release of: a. GABA. b. Serotonin. 13. One of the most salient determinants of a high level of nicotine dependence using the Fagerström Test for Nicotine Dependence is: a. The total number of cigarettes smoked. b. Smoking within 5 minutes of waking. c. The type/brand of cigarette smoked. d. Smoking more in the evening hours. 14. After stopping smoking, symptoms of nicotine withdrawal generally peak in about: a. 4-5 hours. b. 10-12 hours. c. 2-3 days. d. 6-7 days. 15. How long after a quit attempt should a clinician schedule follow-up contact with a patient? c. Epinephrine. d. Acetylcholine.
a. Within the first week. b. Within the first month. c. Within 3 months. d. Within 6 months.
c. Geographic tongue. d. Dentinal sensitivity.
Course Code: DCA03TC
Page 89
EliteLearning.com/Dental
Powered by FlippingBook